Zymeworks Inc
NASDAQ:ZYME

Watchlist Manager
Zymeworks Inc Logo
Zymeworks Inc
NASDAQ:ZYME
Watchlist
Price: 14.3 USD 0.7% Market Closed
Market Cap: 989m USD
Have any thoughts about
Zymeworks Inc?
Write Note

Zymeworks Inc
Non-Reccuring Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Zymeworks Inc
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Zymeworks Inc
NASDAQ:ZYME
Non-Reccuring Items
-$17.3m
CAGR 3-Years
N/A
CAGR 5-Years
-85%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Non-Reccuring Items
-$1.6B
CAGR 3-Years
-7%
CAGR 5-Years
25%
CAGR 10-Years
-15%
Gilead Sciences Inc
NASDAQ:GILD
Non-Reccuring Items
-$10B
CAGR 3-Years
-242%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Non-Reccuring Items
$243m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Non-Reccuring Items
-$4.6B
CAGR 3-Years
N/A
CAGR 5-Years
-175%
CAGR 10-Years
-51%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Non-Reccuring Items
-$219.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-35%
No Stocks Found

Zymeworks Inc
Glance View

Market Cap
1B USD
Industry
Biotechnology

Zymeworks Inc. is a biopharmaceutical company. The company is headquartered in Middletown, Delaware and currently employs 286 full-time employees. The company went IPO on 2019-06-24. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The firm operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. The Company’s ZymeLink is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.

ZYME Intrinsic Value
18.33 USD
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Zymeworks Inc's Non-Reccuring Items?
Non-Reccuring Items
-17.3m USD

Based on the financial report for Sep 30, 2024, Zymeworks Inc's Non-Reccuring Items amounts to -17.3m USD.

What is Zymeworks Inc's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 5Y
-85%

Back to Top